Calcitonin gene-related peptide levels in saliva of patients with burning mouth syndrome

Journal of Oral Pathology and Medicine

Volumn 38, Issue 1, 2009, Pages 29-33

  Zidverc Trajkovic, Jasna ^a   Stanimirovic, Dragan ^b   Obrenovic, Radmila ^a   Tajti, János ^c   Vécsei, László ^c   Gardi, János ^c   Németh, József ^d   Mijajlovic, Milija ^a   Sternic, Nadezda ^a   Jankovic, Ljiljana ^b  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c UNIVERSITY OF SZEGED   (Hungary)

^d UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Burning mouth syndrome; Calcitonin gene related peptide; Saliva

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE;

ADULT; AGED; ARTICLE; BURNING MOUTH SYNDROME; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH PAIN; NERVE CONDUCTION; NEUROLOGIC DISEASE; PRIORITY JOURNAL; SALIVA; SALIVA ANALYSIS; SALIVA LEVEL; TRIGEMINAL NERVE;

ADULT; AGED; AGED, 80 AND OVER; BASAL GANGLIA DISEASES; BIOLOGICAL MARKERS; BRAIN INFARCTION; BURNING MOUTH SYNDROME; CALCITONIN GENE-RELATED PEPTIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE DEGENERATION; POLYNEUROPATHIES; SALIVA; SECRETORY RATE; TRIGEMINAL NERVE; VASODILATION; VASODILATOR AGENTS;

EID: 58149156549     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2008.00721.x     Document Type: Article

References (29)

1. Headache Classification subcommittee of the International Headache society. The international classification of headache disorders, 2nd edn. Cephalalgia 2004 24 (Suppl. 1 1 160.
2. Lipton JA, Ship JA, Larach-Robinson D. Estimated prevalence and distribution of reported orofacial pain in the United States. J Am Dent Assoc 1993 124 : 115 21.
3. Zakrzewska JM. The burning mouth syndrome remains an enigma. Pain 1995 62 : 253 7.
4. Forssell H, Jaaskelainen S, Tenovuo O, Hinkka S. Sensory dysfunction in burning mouth syndrome. Pain 2002 99 : 41 7.
5. Gao S, Wang Y, Wang Z. Assessment of trigeminal somatosensory evoked potentials in burning mouth syndrome. Chin J Dent Res 2000 3 : 40 6.
6. Lauria G, Majorana A, Borgna M, et al. Trigeminal small-fiber sensory neuropathy causes burning mouth syndrome. Pain 2005 115 : 332 7.
7. Hagelberg N, Forssell H, Rinne JO, et al. Striatal dopamine D1 and D2 receptors in burning mouth syndrome. Pain 2003 101 : 149 54.
8. Uddman R, Edvinsson L, Ekblad E, Hakanson R, Sundler F. Calcitonin gene-related peptide (CGRP): perivascular distribution and vasodilatatory effects. Regul Pept 1986 15 : 1 23.
9. Brain SD. Calcitonin gene-related peptide (CGRP) antagonists: blockers of neuronal transmission in migraine. Br J Pharmacol 2004 142 : 1053 4.
10. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of human during migraine headache. Ann Neurol 1990 28 : 183 97.
11. Juhasz G, Zsombok T, Modos EA, et al. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain 2003 106 : 461 70.
12. Edvinsson L. Blockade of CGRP receptors in the intracranial vasculature: a new target in the treatment of headache. Cephalalgia 2004 24 : 611 22.
13. Edvinsson L, Uddman R. Neurobiology in primary headaches. Brain Res Rev 2005 48 : 438 56.
14. Edvinsson L. Novel migraine therapy with calcitonin gene-regulated peptide receptorantagonists. Expert Opin Ther Targets 2007 11 : 1179 88.
15. Link AS, Kuris A, Edvinsson L. Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system. J Headache Pain 2008 9 : 5 12.
16. Nemeth J, Oroszi G, Jakab B, et al. 125I-labeling and purification of peptide hormones and bovine serum albumin. J Radioanal Nucl Chem 2002 251 : 129 33.
17. Nemeth J, Gorcs T, Helyes Z, et al. Development of a new sensitive CGRP radioimmunoassay for neuropharmacological research. Neurobiology 1998 6 : 473 5.
18. Scala A, Checchi L, Montevecchi M, Marini I, Giamberardino MA. Update on burning mouth syndrome: overview and patient management. Crit Rev Oral Biol Med 2003 14 : 275 91.
19. De Moura SA, De Sousa JM, Lima DF, Negreiros AN, Silva F de V, Da Costa LJ. Burning mouth syndrome (BMS): sialometric and sialochemical analysis and salivary protein profile. Gerodontology 2007 24 : 173 6.
20. Yilmaz Z, Renton T, Yiangou Y, et al. Burning mouth syndrome as a trigeminal small fibre neuropathy: increased heat and capsaicin receptor TRPV1 in nerve fibres correlates with pain score. J Clin Neurosci 2007 14 : 864 71.
21. Greco R, Tassorelli C, Sandrini G, Di Bella P, Buscone S, Nappi G. Role of calcitonin gene-related peptide and substance P in different models of pain. Cephalalgia 2008 28 : 114 26.
22. Fusayasu E, Kowa H, Takeshima T, Nakaso K, Nakashima K. Increased plasma substance P and CGRP levels, and high ACE activity in migraineurs during headache-free periods. Pain 2007 128 : 209 14.
23. Grushka M, Sessle BJ. Burning mouth syndrome. Dent Clin North Am 1991 35 : 171 84.
24. Carrington J, Getter L, Brown RS. Diabetic neuropathy masquerading as glossodynia. J Am Dent Assoc 2001 132 : 1549 51.
25. Moore PA, Guggenheimer J, Orchard T. Burning mouth syndrome and peripheral neuropathy in patients with type 1 diabetes mellitus. J Diabetes Complications 2007 21 : 397 402.
26. Jaaskelainen SK, Rinne JO, Forssell H, et al. Role of the dopaminergic system in chronic pain - a fluorodopa-PET study. Pain 2001 90 : 257 60.
27. Albuquerque R, De Leeuw R, Carlson C, Okeson J, Miller C, Andersen A. Cerebral activation during thermal stimulation of patients who have burning mouth disorder: an fMRI study. Pain 2006 122 : 223 34.
28. Fisher CM. Lacunar infarcts - an overview. Cerebrovasc Dis 1991 1 : 311 20.
29. Welch KM. Concepts of migraine headache pathogenesis: insights into mechanisms of chronicity and new drug targets. Neurol Sci 2003 24 : 149 53.